KRAS and familial pancreatic carcinoma: Notably, 28 μg/ml of liposome-GGTI combined with 2.5 μM FTI suppressed cell proliferation by approximately 80% in KRAS mutant pancreatic cancer cells—an effect neither agent achieved on its own.